ClinicalTrials.gg
CompletedNCT01066676Updated Jul 10, 2012

Dexibuprofen 400 mg Sachet Versus Ibuprofen 400 mg Sachet in Patients With Osteoarthritis of the Hip or Knee

A Phase 4 interventional study of Dexibuprofen and Ibuprofen in Osteoarthritis of the Hip or Knee, sponsored by Gebro Pharma GmbH. Completed at 2 sites in Austria. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-07-10.

Sponsored by Gebro Pharma GmbH · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
482
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Medical condition under investigation: Osteoarthritis of the hip or knee

Number of patients planned: 480 adult patients

Main objective: To evaluate and compare the tolerability profile of Dexibuprofen Gebro 400 mg powder for oral suspension compared to Ibuprofen 400 mg in patients with painful osteoarthritis of the hip or knee

Secondary objectives: To compare the overall efficacy of Dexibuprofen Gebro 400 mg powder for oral suspension compared to Ibuprofen 400 mg in patients suffering from different complaints due to painful osteoarthritis of the hip or knee

02

Conditions studied

  • Osteoarthritis of the Hip or Knee

Browse trials for

03

In context

Osteoarthritis, Hip

641 studies on the registry are indexed under Osteoarthritis, Hip; 120 are open to participants now.

This study's enrollment of 482 is above the median of 90 across 457 interventional studies indexed under Osteoarthritis, Hip.

Browse Osteoarthritis, Hip studies →

Lead sponsor

Gebro Pharma GmbH is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male or female patients aged between 18 and 75 years
  • everyday joint pain for the past three months
  • global pain intensity in the involved joint (hip or knee) of "moderate" to "severe" within the last 48 h

Exclusion criteria

Exclusion Criteria:

  • acute inflammation or ischaemic necrosis
  • paget's disease, chondrocalcinosis, ochronosis of the hip/knee joint
  • slowly progressing hip/knee arthropathy in particular of tuberculosis aetiology
  • hip/knee arthropathy due to diabetes mellitus
  • Charcot's joint
  • villous synovitis
  • chondromatosis of the synovium
  • patients with existing gastritis or existing ulcers or bleedings in the gastrointestinal tract or patients with history of gastrointestinal ulcers or gastrointestinal haemorrhage in the past 6 months
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
482 participants (actual)

Study arms

  • Experimental
    Dexibuprofen

    Dexibuprofen 400 mg powder for oral suspension

    Drug: Dexibuprofen

  • Active comparator
    Ibuprofen

    Ibuprofen 400 mg powder for oral suspension

    Drug: Ibuprofen

Interventions

  • 400mg powder for oral suspension, daily dose 800mg

  • 400mg, powder for oral suspension, daily dose 1600mg

06

What researchers measure

Primary outcomes

  1. Tolerability profile of Dexibuprofen Gebro 400 mg powder for oral suspension compared to Ibuprofen 400 mg in patients with painful osteoarthritis of the hip or knee

    Time frame: 14 days

Secondary outcomes

  1. Overall efficacy of Dexibuprofen Gebro 400 mg powder for oral suspension compared to Ibuprofen 400 mg in patients suffering from different complaints due to painful osteoarthritis of the hip or knee

    Time frame: 14 days

07

Study locations

2 sites
  • Rehabzentrum für Erkrankungen des rheumat. Formenkreises
    Bad Hofgastein, Salzburg 5630, Austria
  • Rheuma Zentrum Favoriten
    Vienna, 1100, Austria
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2010
First posted
Feb 10, 2010
Start
Oct 2009
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Last update
Jul 10, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01066676
Lead sponsor
Gebro Pharma GmbH
Responsible party
Sponsor
First posted
Feb 10, 2010
Start date
Oct 2009
Primary completion
Jun 2012
Completion
Jun 2012
Last update
Jul 10, 2012

Study contacts

Reinhold Hawel, MD
principal investigator · Rehabilitationszentrum, Bad Hofgastein

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexibuprofen

Start the discussion